Mass-producible immune cells kill patient-derived colorectal tumors in mice
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Off-the-shelf and mass-producible immune cells fight solid human tumors engrafted in mice. The Kobe University development is a significant contribution toward faster, cheaper cancer immunotherapy.
The body employs an army of immune cells to fight cancer, and one of its major forces is T cells. They are also the target of modern cancer immunotherapies that try to increase T cells' ability to find and attack cancer cells. When modifying T cells, current techniques require extracting a patient's own T cells from blood, modifying them in the lab and reintroducing them into the patient, which is not only very expensive but also costs valuable time.
Researchers have considered turning to a subclass of T cells called "gamma-delta (γδ) T cells" that don't need to be tailored to each individual patient but can be harvested from a donor and used in other people. However, these cells are far fewer in number, making the harvesting approach infeasible, and they also cannot be directly multiplied well in the lab.
Kobe University stem cell researcher Takashi Aoi says, "Based on our experience with induced pluripotent stem cells, also called iPS cells, we thought that we could approach this issue by creating such easily storable and growable cells from these specific T cells, and then only turning them back into T cells when actually needed."
Since T cells modify their DNA during development to target a specific threat, creating iPS cells from cancer-specific T cells also means that all their descendants will retain that specificity. Essentially, the process amounts to creating an army of clones from one good cancer fighter.
Turning rare cells into a supply
In their latest paper in the journal Stem Cell Reports, Aoi and his team show that they could create iPS cells from the subclass of T cells that can be used across patients and reproducibly turn them back into those T cells with an overall 80,000-fold multiplication. Importantly, they achieved this without relying on animal cells or extracts, which is a requirement for clinical applications.
Their study was also the first to show, on a small preclinical scale, that the resulting T cells attack and shrink human patient-derived colorectal cancer tumors implanted in mice.
"Cancers from cell culture lines don't have the same drug insensitivities as actual cancers and also don't emulate the physical barriers that actual tumors have. That's why patient-derived organoids are highly significant for evaluating new cancer treatment approaches," explains the study's first author, Ryoko Futai.
Testing whether the cells can travel
When they designed the study, the Kobe University team imagined that their approach would be used to fight metastasizing cancers. Therefore, they also checked whether their T cells would find their targets not only when administered close to the tumor but also when administered intravenously a week after the tumor was implanted.
Indeed, even in this setting, tumor weights decreased by 43% to 92% in the three mice tested. Futai says, "This suggests potential for future systemic therapy. We believe this achievement represents an important step toward the development of a new immunotherapy for solid tumors."
At the current stage, the study was conducted on a small scale, with only three or four mice in each experiment and tumor models derived from only two different patients. This is especially important because colorectal cancer tumors are known for their high variability.
"This study is a preclinical investigation demonstrating the potential of using iPS cell-derived T cells and is not yet at a stage where it can be used on patients," cautions Futai.
Limits now, combinations later
But by conducting further studies using these easily multipliable and highly standardized cells, the Kobe University development may also be used to elucidate where the variability comes from and what steps to take to counter it.
Aoi concludes, "Furthermore, by combining this approach with cell modification techniques such as CAR therapy, we hope that this research will eventually lead to the development of new therapeutic possibilities for patients with solid tumors."
Publication details
Allogeneic iPSC-derived γδT cells demonstrate antitumor efficacy against patient-derived tissues, Stem Cell Reports (2026). DOI: 10.1016/j.stemcr.2026.103018
Journal information: Stem Cell Reports
Key medical concepts
Induced Pluripotent Stem Cells
Clinical categories
OncologyAllergy and immunology Provided by Kobe University Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Mass-producible immune cells kill patient-derived colorectal tumors in mice (2026, July 23) retrieved 24 July 2026 from https://medicalxpress.com/news/2026-07-mass-immune-cells-patient-derived.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.